Talk:CREATES Act

Note
In response to the note at my talk page here... I am not a big fan of articles about bills (which may never become law). The refs are also not great - there are two pieces by a Forbes contributor (they don't count toward N), some opinion pieces (Bloomberg and WaPo), two refs from the Axios blog, and the bill itself. Oh and the intercept which is also bloggy. So.. hm.

How would you feel about adding a short section on this to Prescription drug prices in the United States and redirecting there? Jytdog (talk) 22:26, 12 February 2018 (UTC)


 * Yeah those seem reasonable points. I think highlighting the REMS process for review as well as sampling and the litigation regarding this for pharmaceutical companies embedded to block generic production seem the main "market place" factors driving the bill. Overall these are ingrained in the current system and notable in themselves in any article relating to the topic - Prescription drug prices in the United States as you mentioned. I think it also relates pretty relevantly to February 2018 budget package and could be included as a snippet in there. Overall I think there's a good "variety" of sources available on this topic that I found when searching, although a good amount could be considered "opinion" / "spin" due to it being a proposed bill that has yet to hit the floor. Shaded0 (talk) 14:10, 13 February 2018 (UTC)